why choose us

First received: January 03, 2023

Clinical Trial: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Diffuse Large B-Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Brief Summary: This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory).Loncastuximab tesirine is a monoclonal antibody, loncastuximab, linked to a toxic agent called tesirine.Loncastuximab attaches to anti-CD19 cancer cells in a targeted way and delivers tesirine to kill them.Mosunetuzumab is a monoclonal antibody that may interfere…

Read more